Richard Lee
Executive Director of Preclinical Sciences Eli Lilly/Verve
- Role
- Executive Director at Eli Lilly and Company
- Location
- Carlsbad, CA, US
- LinkedIn followers
- 500 followers
About Richard Lee
I am a dedicated PHARMACEUTICS RESEARCH SCIENTIST with over 17 years’ experience developing drug candidates and diagnostic solutions targeting cardiometabolic diseases across a wide range of experiments.While my passion for preclinical research drives my accomplishments in drug discovery, I have expertise across the full drug-discovery lifecycle, from conceptualization to clinic. WHO I AM: ⇨ Versatile DRUG DEVELOPER with cross-functional experience in each step of the development process: science, business development, executive presentations, clinical assay development, and regulatory-report writing.⇨ Astute PROJECT MANAGER who understands deliverables and coordinates project work with departmental, functional, and external stakeholders, consistently exceeding goals and quotas.⇨ Empowering MENTOR, possessing ability to manage a team of scientists who deliver revenue-generating, publishable results. MY ACCOMPLISHMENTS: Assisted in $250M upfront sale,$1.3B milestones, and double-digit sales royalties for licensing of Angptl3-LRx to Pfizer as preclinical science lead for business development negotiations. Published 56 academic and scientific articles in peer-reviewed medical journals and books. Leadership committee member of AstraZeneca/Ionis collaboration to identify therapeutic targets for metabolic/cardiovascular disease. Led preclinical efforts in 1 of 3 clinical drug trials and 1 of 2 drugs in development candidate identification. Independently designed/executed in vivo studies that identified biomarkers for 3 dyslipidemia programs and 2 NAFLD/NASH programs.CORE COMPETENCIES:NAFLD/NASH | Drug Development | Assay Development | Preclinical ResearchClinical Research | Drug Discovery | Pharmacology | RNA Interference | Beta Cell Dysfunction NOTABLE PUBLICATIONS:Antisense Oligonucleotide Inhibition of Apolipoprotein Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans. Circulation Research 2013 May 24;112(11):1479-90. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017 Jul genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1. PLoS Genet. 2018 Oct 29;14(10).Targeted delivery of antisense oligonucleotides to pancreatic β-cells. Science Advances. 2018 Oct 17 17;4(10) eaat3386.For full list of publications, please see Publications List.
Experience
Executive Director
Oct 2025 — Present · Boston, MA, US
Transitioned to Eli Lilly following it\'s acquisition of Verve Therapeutics
Education
Western Oregon University
Bachelor's degree, Biology
1993 — 1997
Wake Forest University School of Medicine
Doctor of Philosophy - PhD, Cellular and Molecular Pathobiology
1998 — 2004
Skills
- Molecular Biology
- Biomarkers
- Cell Biology
- Lifesciences
- Biotechnology
- Drug Development
- Cell
- Drug Discovery
- Life Sciences
- Ind
- Clinical Development
- In Vivo
- Pharmacology
- Animal Models
- In Vitro
- Assay Development
- Toxicology
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.